A comprehensive meta-analysis of 12 new-generation antidepressants has shown sertraline and escitalopram have clear advantages in terms of efficacy and acceptability, while reboxetine was shown to be the significantly less efficacious than the other 11 drugs. The

Adheris, Inc., a leader in patient adherence and education programs, announced today the results of a new study that examined adherence rates among patients on SSRI/SNRI antidepressant therapy.
Study results showed that patients new to antidepressant treatment

Auspex Pharmaceuticals, a developer of next-generation medicines with improved safety and performance through the targeted deuteration of clinically validated drugs, today announced positive results from its Phase 1 clinical trial evaluating SD-254, a Selective Serotinin-Norepinephrine Reuptake Inhibitor (SNRI). Auspex is developing SD-254, a deuterium-substituted version of venlafaxine, for the treatment